Array BioPharma’s ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs Array BioPharma (NASDAQ: ARRY) today announced ...
Array BioPharma Inc.'s p38-alpha kinase inhibitor, ARRY-797, hit its primary endpoint of reducing pain more than placebo in a Phase II proof-of-concept trial in 157 patients with knee pain due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results